some patients for years, and with agreement of the treating physicians, they might not be willing to change to newer medications. It also may be related to physician' prescription pattern, patient preferences and local regulations, etc. Multiple use of different antidepressants over years is another issue. All these may be a major challenge in data analysis and interpretation.
REVIEWER
Julian Elliott Cochrane Australia, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia I have collaborated with Prof Salanti on a Cochrane project investigating statistical approaches to the updating of metaanalyses.
REVIEW RETURNED
02-Jul-2018
GENERAL COMMENTS
The authors propose a retrospective study comparing network metaanalyses (NMA) of anti-depressants at 5 yearly intervals with major clinical practice guidelines (CPGs) and US prescription data. The authors should be commended for the objectives of this metaepidemiological study, which aims to highlight important gaps between the accumulation of research and subsequent guideline recommendations and practice.
The key challenge for this study is the complexity of guideline development and practice behaviours. Efficacy and acceptability are some, but not all the factors that must be considered when developing guideline recommendations. Similarly, there is well characterised complexity in the translation of guideline recommendations into prescription practice. The authors acknowledge these and other limitations, but I am still left with some concerns regarding the conclusions that will be possible when the planned comparisons have been completed.
I have a recommendation and two additional points for consideration.
First, I believe the plan to repeat the NMA at 5-yearly intervals is problematic. suggest that to achieve the study aims, the NMAs should be performed at more frequent intervals (optimally for each year).
Second, for consideration only, I wonder about an analysis that focusses not so much on 'gaps' between the NMAs and CPGs, but time from a change in NMA ranking to change in CPG recommendation. This would provide important metaepidemiological information on delays in the evidence ecosystem over the last 20-30 years.
Third, the weaknesses of the MEPS dataset acknowledged by the authors are significant, particularly that the data are not able to be disaggregated by initial versus continuing treatment. This may lead to erroneous conclusions about delays in prescription practice change. I wonder whether the analysis of this dataset is worth the effort, or could at least be supplemented by a more appropriate dataset with data on antidepressant initiations.
Additional points:
• The proposed study is not a NMA alone, but given the important role NMA plays in the study, the authors could consider including NMA in the title of the manuscript.
• 'Extracting' and coding CPG recommendations is a complex task and needs further description.
• The definition of trial completion year seems to suggest that for studies with a known completion year after the proposed 'NMA year', data published after the 'NMA year' will be included in the relevant NMA. Please clarify.
• Please clarify the text to indicate that individuals taking mood stabilisers and antipsychotics will be excluded from denominator data.
• Please clarify whether the MEPS data will be compared to APA recommendations only.
• For the statement regarding regarding systematic reviews being out of date at time of publication the authors should reference Shojania, Ann Int Med 2007, which estimated that 7% of SRs were out of date when published.
• A better citation is needed for the MEPS dataset.
• The potential contribution of this work to living guidelines could reference recent publications on this topic.
• Please describe the role of the funder in the study.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 (Reviewer Name: Kee-Hsin Chen Institution and Country: Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taiwan) This is a manuscript proposing a study protocol in comparison of the efficacy and acceptability of new generation antidepressants by network meta-analyses, recommendation from international clinical practice guidelines, and prescription patterns of antidepressants data by representative samples in USA. The prospective study results may provide the situation between evidence and real-world clinical practices. In addition, it may give future direction to narrow the gaps from evidence to implementation. I believe the study is a good start; however, there are some comments worthwhile to mention.
RESPONSE:
We thank the reviewer for these positive comments.
1. In regard to identify and extract recommendations in guidelines, research team considers extracting recommendations for specific antidepressants from internationally representative guidelines (APA, NICE, BAP and CANMAT). I would suggest describing the details of inclusion and exclusion criteria in this protocol, for example, inclusion of guidelines developed from rigor guideline development methodology and exclusion of expert consensus guidelines. RESPONSE: We thank the reviewer for this insightful suggestion. As suggested, we have added some information about the inclusion and exclusion criteria in the text as follows (page 8, paragraph 2):
English written guidelines proposed by government agencies (such as National Institute for Health and Care Excellence), or professional academic societies (such as American Psychiatric Association) will be included.
2. The appraisal tool (or method) used to evaluate the quality of included guidelines should be stated. In addition, it is desirable to have detail items of data extraction described in the protocol. RESPONSE: We appreciate these helpful suggestions. With regard to the appraisal of guidelines, we checked the items of relatively widely accepted guideline appraisal instruments including AGREE II, but found it hard to apply them because of ambiguity and subjectivity of the included items. We therefore decided not to use it but describe the development methodology of each guideline. This information was added in the text (page 8, paragraph 2):
Due We appreciate the opportunity to clarify this point. This meta-epidemiological study is basically a descriptive study, which will visually explore the differences between evidences from cumulative network meta-analysis, guideline recommendations and real-world prescriptions. As a result, there would be no formal statistical methods that are going to be used in the study.
4. Some confounders that may influence the prescription should be of concern, for example, certain antidepressants may be effective in some patients for years, and with agreement of the treating physicians, they might not be willing to change to newer medications. It also may be related to physician' prescription pattern, patient preferences and local regulations, etc. Multiple use of different antidepressants over years is another issue. All these may be a major challenge in data analysis and interpretation. RESPONSE: We agree with the reviewer's comments, and we have acknowledged the potential limitations in the "Discussion" section as follows (page 12, last paragraph):
There are some limitations to our study.
First, MEPS does not allow us to extract very precise information, including whether the antidepressant is being used as first-line or later treatments. This may lower the comparability between the cNMA of acute phase treatment studies of unipolar depression and the real world practices, as patients on continuation/maintenance treatment may continue using the same antidepressants after guideline recommendations for acute phase treatment change. However, it must be noted that three quarters of patients who initiate antidepressant treatment discontinue the drug within 90 days 54 , suggesting that the majority of the patients in MEPS database represent initial prescriptions. (…) Lastly, the reasons behind the differences between evidence and practice may be very complicated and we will need to factor in various potential confounding factors such as the side-effects, marketing efforts of pharmaceutical companies and local regulations such as price or patent status of a particular drug.
We have also discussed the influence of potential confounder "multiple use of different antidepressants". We have therefore decided to include patients on monotherapy only. We have clarified it in the "Real-world prescriptions data extraction" section (page 10, last paragraph):
We will use the total number of patients with the diagnosis of depression and who are on antidepressant monotherapy but not taking mood stabilizers and antipsychotics (listed above) concomitantly at this round as denominator, and the prescription for a particular drug as monotherapy as numerator.
Reviewer 2 (Reviewer Name: Julian Elliott Institution and Country: Cochrane Australia, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia) The authors propose a retrospective study comparing network meta-analyses (NMA) of antidepressants at 5 yearly intervals with major clinical practice guidelines (CPGs) and US prescription data. The authors should be commended for the objectives of this metaepidemiological study, which aims to highlight important gaps between the accumulation of research and subsequent guideline recommendations and practice. The key challenge for this study is the complexity of guideline development and practice behaviours. Efficacy and acceptability are some, but not all the factors that must be considered when developing guideline recommendations. Similarly, there is well characterised complexity in the translation of guideline recommendations into prescription practice. The authors acknowledge these and other limitations, but I am still left with some concerns regarding the conclusions that will be possible when the planned comparisons have been completed.
RESPONSE:
We thank the reviewer for her careful review and the overall broad perspectives provided. We agree with the reviewer that these are very important limitations when interpreting the results of this study, which we have tried to cover in the Methods and Discussion sections of the protocol. Please see our response to the first reviewer above. With the caveat of feasibility, I suggest that to achieve the study aims, the NMAs should be performed at more frequent intervals (optimally for each year).
We appreciate the reviewer's suggestions. We agree that 'CPG 2009' (guidelines published in 2009) might take updated evidences not covered in 'NMA 2005' into consideration. Please note however that we plan to run NMA every 5 years and we will use a figure to show the trend of evidence change and prescription change by connecting these 5-yearly estimates. When we make comparisons, we will consider these trends as well.
Second, for consideration only, I wonder about an analysis that focusses not so much on 'gaps' between the NMAs and CPGs, but time from a change in NMA ranking to change in CPG recommendation. This would provide important meta-epidemiological information on delays in the evidence ecosystem over the last 20-30 years.
We thank the reviewer for this very important comment. Although the exact lag time between change in NMA rankings and CPG recommendation is very critical information, such an estimate is only possible if there is straightforward association between rankings and the recommendations (e.g., the trend of rankings is approximately the same with the trend of guideline recommendations ('parallel line' in figure) , only with delayed trend). However, as the reviewer herself has commented, quite a few factors may affect the prescription patterns other than NMA rankings, so that the direct association may or may not be observed. If the factors other than time contributed to the difference between rankings and recommendations, it would be hard to tell the exact time lag. Consequently, we have decided not to set the lag time as our primary aim, but to investigate this lag more qualitatively, from the view of overall change.
We appreciate these helpful suggestions. 
